Determine exposure to HBV infection. May be helpful in determining which patients are at risk for HBV reactivation and would benefit from prophylactic nucleoside analog treatment prior to initiation of immunosuppression therapy.
Qualitative Chemiluminescent Immunoassay
Within 24 hours
New York DOH Approval Status
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport tube. (Min: 0.5 mL) Also acceptable: K2EDTA plasma.
Heparinized plasma. Specimens containing particulate material. Heat-inactivated, severely hemolyzed, or lipemic specimens.
After separation from cells: Ambient: Unacceptable; Refrigerated: 1 week; Frozen: Indefinitely (avoid repeated freeze/thaw cycles)
|Hepatitis B Core Antibodies, Total||Negative|
This assay should not be used for blood donor screening, associated re-entry protocols, or for screening Human Cell, Tissues and Cellular and Tissue-Based Products (HCT/P).
This assay tests for IgG and IgM antibodies, but does not differentiate between them.
|Component Test Code*||Component Chart Name||LOINC|
|0020091||Hepatitis B Core Antibodies, Total||13952-7|
- Anti Core Antibodies
- Anti-Hepatitis Bc
- Antibody to Hepatitis Bc
- Core Antibody IgG/IgM
- HBV Core Total
- Hep B Core Ab IgG/IgM, Hep Bc Ab IgG/IgM
- Hep B Core Total Ab
- Hepatitis B Immune Status Profile, Serum